EP0374210A1 - Flevoxate and derivatives for erectile dysfunctions - Google Patents
Flevoxate and derivatives for erectile dysfunctionsInfo
- Publication number
- EP0374210A1 EP0374210A1 EP89904810A EP89904810A EP0374210A1 EP 0374210 A1 EP0374210 A1 EP 0374210A1 EP 89904810 A EP89904810 A EP 89904810A EP 89904810 A EP89904810 A EP 89904810A EP 0374210 A1 EP0374210 A1 EP 0374210A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- methylflavon
- treatment
- erectile
- erectile dysfunctions
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Definitions
- This invention relates to the use of 3-methyl-f la- von-8-carboxyl ⁇ c acid and derivatives thereof for the preparation of a drug for the treatment and for the diagnosis of erectile impotence.
- the invention relates to pharma ⁇ ceutical compositions for the treatment of erectile impotence containing as the active principle 3-methylfla- von-8-carboxyl ⁇ c acid or a derivative thereof of formula I
- A is a linear or branched C -C alkyl residue
- Z is a dimethylamino, diethylammo, di-n-propylamino, di- lsopropylammo, piperidmo or morpholmo residue, or pharmaceutically acceptable salts thereof.
- Flavoxate is a very well tolerated drug; the large therapeutic index found in preclinical studies (C. Pietra et al., II Farmaco Ed. Prat., 4_1, 267, (1986)) and the absence of serious side effects during clinical application, attest its excellent tolerability. Particularly, cardiocirculatory complica ⁇ tions have never been reported. 3-methylflavon-8-carbo- xylic acid(MFCA) is the main metabolite of flavoxate. In terms of pharmacokinetics and - dynamics MFCA is most similar to flavoxate.
- Erectile dysfunction is a well known and common disease, of vascular, hormonal, neurogenic or psychogenic origin which causes impaired penile erection.
- the insufficient erectile ability of the penis has serious implications for psychological, physical and social well-being of the afflicted individuals. Self confidence in particular, and quality of life in general, are strongly reduced.
- Prosthetic devices that are implanted in the penis to mimic erection or are located outside in the scrotal sac or in an adjacent area to stimulate for instance to trasmitting electrical energy to the nervi erigentes.
- Pharmacological substances which are also injected directly into the corpora cavernosa, where they increase the inflow of blood and consequently generate tumescence of the penis, are also used.
- Human tissue was obtained from patients undergoing penile prothesis implantation.
- Biopsies of human corpus cavernosum tissue were obtained in the operating room and immediately placed in chilled (4°C) physiological salt solution of the following millimolar composition: NaCl 118.3; KC1 4.7; Mg ⁇ O 0.6; KH PO 1.2; CaCl 2.5; NaHCO 25.0; Calcium EDTA 0.026 and glucosio 11.1.
- the solution is gassed with 95% 0 , 5% CO ; pH maintained at 7.4 and temperature at 37°C.
- Isometric tension was measured throught the experiment with a tension transducer (Grass FT03, Quincy, MA) .
- the strips of corpus cavernosum were fixed with silk ties on one end to the electrode support and the other end to a wire connected to the force transducer.
- the strips were allowed to equilibrate for a period of approximately three hours.
- the optimal isometric tension for contraction was determined during this period by stepwise stretching of the tissue followed by
- Drugs were provided in powder form. Stock solutions were made in distilled water. For papaverine and flavoxate
- Flavoxate up to 10 M, induced relaxation of HCC contracted with norepinephrine, PG F2 alpha or potassium. Maximal relaxations to this concentration were: 73.1 +/- 7.7%, 66 +/- 13.2%, and 55.5 +/- 23% of maximal relaxation, respectively (see figures 1-3).
- the threshold for the response to flavoxate was approximately 3 x 10 M. The relaxation response was slow in onset and several minutes were required before the maximal relaxation
- 3-methylflavon-8-carboxylic acid and its basic esters of formula I, particularly flavoxate may be conveniently used in human therapy for the treatment of erectile impairments.
- pharmaceutical compositions suited for the oral, topical or parenteral (intracavernous) administration are provided.
- the oral administration is particularly convenient for its compliance and it is moreover useful as support therapy in patients who otherwise undergo papaverine or alpha-blockers injection. This regimen allows a reduction of the papaverine and alpha-blocker dosage and improves therefore the safe use of these agents.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2029988 | 1988-04-22 | ||
IT20299/88A IT1217190B (it) | 1988-04-22 | 1988-04-22 | Composti utili per il trattamento e diagnosi di disfunzioni frettili |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0374210A1 true EP0374210A1 (en) | 1990-06-27 |
Family
ID=11165532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP89904810A Withdrawn EP0374210A1 (en) | 1988-04-22 | 1989-04-19 | Flevoxate and derivatives for erectile dysfunctions |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0374210A1 (ja) |
JP (1) | JPH02504146A (ja) |
KR (1) | KR900700098A (ja) |
AU (1) | AU3438289A (ja) |
HU (1) | HU202754B (ja) |
IT (1) | IT1217190B (ja) |
WO (1) | WO1989010123A1 (ja) |
ZA (1) | ZA892911B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
GB9514465D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
US5503843A (en) * | 1994-04-22 | 1996-04-02 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
GB9423910D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
GB9514473D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
SK154498A3 (en) * | 1996-05-10 | 2000-01-18 | Icos Corp | Carboline derivatives, process for the preparation thereof, pharmaceutical compositions containing same and use of mentioned derivatives as drugs |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
WO2003042216A1 (en) | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
WO2011023287A1 (en) * | 2009-08-27 | 2011-03-03 | Merck Patent Gmbh | Use of faa and its derivatives in cosmetics and dermatology |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0266968A3 (en) * | 1986-11-03 | 1988-08-24 | Gérard G. Cohen | Gelled ointment of vasodilating agent |
-
1988
- 1988-04-22 IT IT20299/88A patent/IT1217190B/it active
-
1989
- 1989-04-19 JP JP1504483A patent/JPH02504146A/ja active Pending
- 1989-04-19 EP EP89904810A patent/EP0374210A1/en not_active Withdrawn
- 1989-04-19 WO PCT/EP1989/000417 patent/WO1989010123A1/en not_active Application Discontinuation
- 1989-04-19 AU AU34382/89A patent/AU3438289A/en not_active Abandoned
- 1989-04-19 HU HU892651A patent/HU202754B/hu not_active IP Right Cessation
- 1989-04-19 KR KR1019890702417A patent/KR900700098A/ko not_active Application Discontinuation
- 1989-04-20 ZA ZA892911A patent/ZA892911B/xx unknown
Non-Patent Citations (1)
Title |
---|
See references of WO8910123A1 * |
Also Published As
Publication number | Publication date |
---|---|
KR900700098A (ko) | 1990-08-11 |
HUT53804A (en) | 1990-12-28 |
HU892651D0 (en) | 1990-11-28 |
AU3438289A (en) | 1989-11-24 |
WO1989010123A1 (en) | 1989-11-02 |
ZA892911B (en) | 1989-12-27 |
IT1217190B (it) | 1990-03-14 |
JPH02504146A (ja) | 1990-11-29 |
HU202754B (en) | 1991-04-29 |
IT8820299A0 (it) | 1988-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100363056B1 (ko) | 사람의성적반응조절용제제 | |
CA2169071C (en) | Methods for modulating the human sexual response | |
RO116346B1 (ro) | Compozitie farmaceutica si metoda de tratament pentru inducerea erectiei la un barbat suferind de impotenta | |
EP0374210A1 (en) | Flevoxate and derivatives for erectile dysfunctions | |
Snyder et al. | Reversal of amitriptyline intoxication by physostigmine | |
West | Curare in man | |
CN111346081B (zh) | 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途 | |
Romeo et al. | Intra-arterial administration of reserpine: its use in patients with Raynaud's disease or Raynaud's phenomenon | |
JP2820737B2 (ja) | 男性不能症の治療用物質 | |
AU3780699A (en) | The treatment of sexual dysfunction in certain patient groups | |
AU3149793A (en) | Pyridylguanidine compounds for treatment of erectile dysfunction | |
US6132753A (en) | Treatment of sexual dysfunction in certain patient groups | |
US4840952A (en) | Method for treatment of male impotence | |
IT9086204A1 (it) | Metodo per la cura dell'impotenza erettiva maschile | |
Browne et al. | The use of intrathecal phenol for muscle spasms in multiple sclerosis: A description of two cases | |
Hall et al. | Vitamin B12 and coordination exercises for combined degeneration of the spinal cord in pernicious anemia | |
Kim et al. | Advances in the treatment of organic erectile dysfunction | |
US6426084B1 (en) | Treatment of sexual dysfunction in certain patient groups | |
Linton | Isonicotinic acid hydrazide: some sensory disturbances during therapy | |
JP3927249B2 (ja) | 鎮痛剤 | |
Alarcón-Segovia et al. | Painful Baker's cysts: Differential diagnosis by scintillation scanning with technetium Tc 99m | |
AU696815C (en) | Methods for modulating the human sexual response | |
Smith et al. | Impending gangrene of the foot following treatment for pruritus of jaundice with ergotamine tartrate: Report of case | |
KILBOURNE | Leg ulcers of unrecognized etiology | |
SU799751A1 (ru) | Способ лечени больных хроническимпРОСТАТиТОМ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19900317 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19910517 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19910928 |